Abstract: The current disclosure provides for techniques and approaches for the generation of autologous mutant neoantigen-specific, TCR-engineered T cells used for adoptive transfer in treatment of cancer patients. Also provided are surrogate cancer cells, which is a personalized cell system that can be used for vaccination and TCR discovery in cancer patients.

Abstract: A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Abstract: Quantum repeaters and network architectures use two concatenated quantum error correction codes to increase the transmission range of quantum information. A block of data qubits collectively encode a second-layer logical qubit according to a second-layer code concatenated with a first-layer code. A first-layer quantum repeater first-layer corrects each data qubit based on a first-layer syndrome extracted therefrom. The first-layer quantum repeater transmits these first-layer-corrected qubits to a second-layer quantum repeater via a quantum communication channel. The first-layer quantum repeater also transmits the first-layer syndromes to the second-layer quantum repeater via a classical communication channel. After extracting a second-layer syndrome from the first-layer-corrected qubits, the second-layer quantum repeater uses the first-layer syndromes and second-layer syndrome to second-layer correct the first-layer-corrected qubits.

Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.

Abstract: Aspects of the disclosure relate to methods for treating sepsis in a patient comprising administering a PLA2G5 targeting molecule, fatty acids, LPA inhibitors, and/or other compositions to the patient.

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Abstract: Embodiments are directed to kits and methods of treating a breast cancer patient with a glucocorticoid receptor antagonist with or without an anticancer agent or compound after the patient has been determined to be susceptible to treatment with the glucocorticoid receptor antagonist.

Abstract: The inventors have made TadA variants with improved activities, such as improved based editing in certain genomic contexts and altered editing window. Aspects of the disclosure relate to a polypeptide comprising SEQ ID NO: 1, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO: 1, wherein the one or more amino acid substitutions comprise a substitution at amino acid (23, 27, 36, 47, 48, 51, 76, 82, 106, 108, 109,110, 111, 114, 119, 122, 123, 126, 127, 146, 147, 152, 154, 155, 156, 157, 161, 166, 167), and combinations thereof.

Abstract: A disinfection system includes a mask chamber and a cassette trolley rail mounted to the mask chamber. The system also includes a mask cassette configured to hold one or more masks and configured to mount to the cassette trolley rail such that the mask cassette translates along the cassette trolley rail. The system also includes a first array of lamps mounted to a first lamp mount within the mask chamber, where the first array of lamps is positioned to emit radiation toward a first side of the mask cassette. The system further includes a second array of lamps mounted to a second lamp mount within the mask chamber, where the second array of lamps is positioned to emit radiation toward a second side of the mask cassette that is opposite the first side of the mask cassette.

Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.

Abstract: The present disclosure provides engineered thymic epithelial cells and cell lines, as well as extracellular vesicles derived therefrom. The disclosure also provides exosomes that display specific surface proteins, and provides methods for using said materials for treating subjects and for identifying cells.

Abstract: Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.

Abstract: This disclosure includes microfluidic devices, systems, and methods for investigating three-dimensional (3D) cell structures (e.g., organoids, spheroids, scaffolds, hydrogels, and the like). Some examples of the present microfluidic devices comprise: a body having a first end, a second end, to lateral edges, an upper side, a lower side, a first layer region between a medial plane of the body and the lower side, and a second layer region between the medial plane and the upper side. In some such examples, the first layer region defines one or more rows of wells, with each well open at the medial plane and having a bottom between the medial plane and the lower side.

Abstract: According to one or more embodiments, a computer implemented method for implementing a convolutional neural network (CNN) using a crosspoint array includes configuring the crosspoint array corresponding to a convolution layer in the CNN by storing one or more convolution kernels of the convolution layer in one or more crosspoint devices of the crosspoint array. The method further includes performing computations for the CNN via the crosspoint array by transmitting voltage pulses corresponding to a vector of input data of the convolution layer to the crosspoint array. Performing the CNN computations further includes outputting an electric current representative of performing a multiplication operation at a crosspoint device in the crosspoint array based on a weight value stored by the crosspoint device and the voltage pulses from the input data. Performing the CNN computations further includes passing the output electric current from the crosspoint device to a selected integrator.

Abstract: Example embodiments allow for networks of hybrid controllers that can be computed efficiently and that can adapt to changes in the system(s) under control. Such a network includes at least one hybrid controller that includes a dynamic sub-controller and a learned system sub-controller. Information about the ongoing performance of the system under control is provided to both the hybrid controller and to an over-controller, which provides one or more control inputs to the hybrid controller in order to modify the ongoing operation of the hybrid controller. These inputs can include the set-point of the hybrid controller, one or more parameters of the dynamic controller, and an update rate or other parameter of the learned system controller. The over-controller can control multiple hybrid controllers (e.g., controlling respective sub-systems of an overall system) and can, itself, be a hybrid controller.

Abstract: Methods for enriching, separating, or enriching and separating isotopes and isotopologues, as well as other chemical species, contained in a supersonic beam are provided. In the methods, a supersonic beam having different isotopes, isotopologues, or other chemical species entrained therein and a beam comprising a matrix material converge on a surface. As the matrix material forms a solid matrix on the surface, heavier isotopes, isotopologues, and/or other chemical species become preferentially embedded in the matrix, while lighter isotopes, isotopologues, and/or other chemical species are preferentially scattered from the surface.

Abstract: Aspects of the present disclosure are directed to methods and compositions for PKC-delta inhibition and cancer immunotherapy. Disclosed are methods for treatment of cancer comprising administration of a PKC-delta inhibitor and an immunotherapy. Also disclosed are compositions comprising a PKC-delta inhibitor and an immunotherapeutic (e.g., an immune checkpoint inhibitor). Further described herein are methods for treating a subject for cancer using an immunotherapy, where the subject was determined to have reduced PKC-delta expression.

Abstract: The sequential infiltration synthesis (SIS) of group 13 indium and gallium oxides (In2O3 and Ga2O3) into polymethyl methacrylate (PMMA) thin films is demonstrated. Examples highlight the an SIS process using trimethylindium (TMIn) and trimethylgallium (TMGa), respectively, with water. In situ Fourier transform infrared (FTIR) spectroscopy reveals that these metal alkyl precursors reversibly associate with the carbonyl groups of PMMA in analogy to trimethylaluminum (TMAl), however with significantly lower affinity. SIS with TMIn and water enables the growth of In2O3 at 80° C., well below the onset temperature of atomic layer deposition (ALD) using these precursors.

Abstract: Some aspects of the present disclosures includes catheters and methods of operating catheters having an elongated body that defines one or more first ports extending through a peripheral surface of the body, a plurality of interior lumens extending longitudinally through the catheter, and one or more tubes each having a sidewall defining a tube lumen in fluid communication with one of the first ports, the one or more tubes configured to shift between a collapsed configuration and an expanded configuration in which the one or more tubes define a cage shape having an unconstrained maximum transverse dimension that larger than a corresponding maximum transverse dimension of the catheter body, where in the collapsed configuration, at least part of tube(s) is radially closer to the catheter body than when in the expanded configuration.